Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001104659-25-058535
Filing Date
2025-06-11
Accepted
2025-06-11 16:06:45
Documents
14
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q/A tm2517714d1_10qa.htm   iXBRL 10-Q/A 51569
2 EXHIBIT 31.1 tm2517714d1_ex31-1.htm EX-31.1 4612
3 EXHIBIT 31.2 tm2517714d1_ex31-2.htm EX-31.2 5236
  Complete submission text file 0001104659-25-058535.txt   250137

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA aeon-20250331.xsd EX-101.SCH 3029
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeon-20250331_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeon-20250331_pre.xml EX-101.PRE 22368
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2517714d1_10qa_htm.xml XML 5301
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-40021 | Film No.: 251039999
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)